KRAS and cancer: Interestingly, in the last few years, CRC has been classified in consensus molecular subtypes (CMS): CMS1 (microsatellite instable tumors), CMS2 (chromosomal instable tumors), CMS3 (KRAS mutated tumors), and CMS4 (cancer with mesenchymal characteristics) [6,17].